Search PubMed⌕ Search

Biomedical subjects

J Jassem

Publications and source records attributed to J Jassem.

102 records · Page 6Linked to original sources
PubMed1980

Some aspects of cell-mediated hypersensitivity in patients with melanoma.

Cell-mediated hypersensitivity in 64 patients with melanoma was assessed by delayed-type skin reactivity to dinitrochlorobenzine (DNCB) and tubercullin as well as by lymphocyte enumerations. The immunological status of the patients was correlated with their clinical stage. The mean absolute and percentage counts of E rosette forming cells were lower in patients than in normal controls. Patients with distant metastases showed lower levels of E rosette forming cells than the patients with localized disease. No differences were found in number of EAC rosette forming cells between melanoma patients and controls. The mean absolute and percentage counts of null cells in melanoma patients in stages II and III were significantly higher than those in controls. Melanoma patients showed reduced skin reactivity to DNCB and normal reactivity to tuberculin. Patients with positive DNCB reactivity showed significantly higher total lymphocyte counts and higher percentages of E rosette forming lymphocytes than patients unreactive to DNCB.

Adult↗
PubMed1980

Skin reactivity to dinitrochlorobenzene in cancer patients.

Delayed skin hypersensitivity to DNCB was evaluated in 179 patients with cancer and in 71 control subjects. Cancer patients had a lower incidence of positive reactions than controls (50.2 vs. 84.5%, p less than 0.001). Incidence of impaired skin reactions in cancer patients varied according to the tumor type. Reactivity was most depressed in patients with lymphatic tumors (23.3% positive results) and least depressed in those with male genitourinary cancer (64.3% positive results). The number of positive results was significantly higher in cancer patients with localized tumor than in those with disseminated disease (60.2% vs. 44.1%, p less than 0.05). DNCB reactivity correlated well with the subsequent course of disease. Incidence of positive results in patients who had remained free of disease after 12 months of follow-up (64.3%) was significantly higher than in patients who had progressive disease (33.3%) or who died of disease (44.8%).

Adolescent↗
PubMedDate not supplied

Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer.

S-100 protein expression is present in various malignant tissues, yet its prognostic relevance is debatable. The aim was to assess in non-small cell lung cancer (NSCLC) patients' prognostic value of S-100 protein considered alone or in relation with other variables. Tumour samples taken from 86 NSCLC patients during resection were assayed for S-100 protein expression with the use of polyclonal DAKO ZO311 antibody. S-100 expression was found in 32 cases (37%). Positive staining was not correlated with clinical characteristics including age, sex, pathology type of tumour, stage and cigarette smoking. There was a tendency for simultaneous expression of S-100 and P53 protein (p=0.06). A median survival rate for the entire group was 2.3 years (95% CI, 0.9-3.6 years). The median and 5-year survival of patients with positive staining for S-100 protein was 1.5 years and 25%, respectively, compared with 3.0 years and 35%, respectively, in the S-100 negative group (p=0.17). In the final model of a multivariate analysis, S-100 protein expression in tumour cells was associated with significantly decreased survival (p=0.005). S-100 protein expression in tumour cells seems to be an independent predictor of poor prognosis in NSCLC patients.

Adult↗
PubMedDate not supplied

Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer.

The efficacy and toxicity of mitomycin C (MMC), ifosfamide, and cisplatin in cervical cancer were evaluated. Between January 1997 and August 2003, 46 patients with locally recurrent, persistent, or disseminated cervical cancer were treated with MMC 6 mg/m(2), ifosfamide 3 g/m(2), and cisplatin 50 mg/m(2) (MIC regimen) repeated every 3 weeks (maximum six cycles). In eight patients (17%), the tumor involved the pelvis alone, in 11 (24%) the pelvis and extrapelvic sites, and 27 (59%) had only distant lesions. A total of 213 MIC cycles were administered (median six cycles per patient). Of the 44 evaluable patients, the overall response rate was 34% (9% complete and 25% partial responses). Median progression-free interval was 6 months (95% confidence interval [CI], 4-7 months), and overall survival was 10 months (95% CI, 6-14 months). Objective response was obtained in two patients (11%) with pelvic relapse within previously irradiated area and in 13 (50%) of those with extrapelvic lesions (P= 0.01). Leukopenia was seen in 59% of patients (grade 3 in 9%). Nonhematologic side effects were mild and relatively infrequent. In conclusion, MIC regimen provides satisfactory efficacy with acceptable toxicity in advanced cervical cancer patients. Better response is seen in lesions outside of the previously irradiated area.

Adult↗
PubMedDate not supplied

[Long-term survival of patients with small cell lung cancer].

The analysis of clinical determinants of long-term survival in small cell lung cancer was investigated in consecutive series of 469 patients included in prospective multicenter clinical trials from 1981 to 1985. Forty eight patients (19.2%) were alive after 2 years from initiation of therapy and among them 27 (5.8%) were disease free. The most important clinical determinants of long-term survival were: extent of disease, performance status and sex. 38 out of 243 patients with limited disease (15.6%) survived for 2 years or more as well as 10 out of 226 patients with extensive disease (4.4%, p less than 0.001), 33 out of 237 patients with WHO performance status 0 and 1 (13.9%), and 15 out of 232 patients with performance status from 2 to 4 (6.4%, p less than 0.01), 29 out of 229 (12.2%) with absence of weight loss before therapy and 19 out of 240 (7.9%) with weight loss (N.S.), 32 out of 392 males (8.2%) and 16 out of 77 females (20.7%, p less than 0.01). Out of 27 disease-free survivors 21 are alive with no sign of malignancy after 3.5 to 7 years from initiation of therapy. Ten patients out of 229 followed up for a minimum 5 years after inclusion to the studies survived this period with no signs of disease. This study confirms the possible curability of small cell lung cancer, especially in patients with favorable prognostic characteristic.

Adult↗
PubMedDate not supplied

[Acute myeloid leukemia during Hodgkin's disease].

A patient with Hodgkin's disease is reported in whom 5 years after establishing of diagnosis acute myeloid leukaemia developed during multistage treatment. The patient died. The authors discuss the problem of leukaemia-inducing influence of intensive radiotherapy and chemotherapy.

Adult↗
PubMedDate not supplied

[Cobalt radioisotope teletherapy of patients with metastases to the brain].

The results are presented of palliative telecobaltotherapy in patients with metastases to the brain. The patients received a dose of 30 Gy in 10 fractions during 2 weeks. Clinical improvement was achieved in 28 out of 33 treated patients (85%). The survival time after the completion of radiotherapy was from 1 to 15 months, mean 5 months.

Adult↗